Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/23735
標題: 探討人類胜肽精胺酸去亞胺酶第四型的胺基酸對受質專一性
Study on the amino acid residues of human peptidylarginine deiminase 4 for substrate specificity
作者: 施凱文
Shih, Kai-Wen
關鍵字: peptidylarginine deiminase 4
人類胜肽精胺酸去亞胺酶第四型
出版社: 生命科學系所
引用: 1. Andrade F, Darrah E, Gucek M, Cole RN, Rosen A, Zhu X: Autocitrullination of human peptidyl arginine deiminase type 4 regulates protein citrullination during cell activation. Arthritis Rheum 2010, 62(6):1630-1640. 2. Arita K, Hashimoto H, Shimizu T, Nakashima K, Yamada M, Sato M: Structural basis for Ca(2+)-induced activation of human PAD4. Nat Struct Mol Biol 2004, 11(8):777-783. 3. Arita K, Shimizu T, Hashimoto H, Hidaka Y, Yamada M, Sato M: Structural basis for histone N-terminal recognition by human peptidylarginine deiminase 4. Proc Natl Acad Sci U S A 2006, 103(14):5291-5296. 4. Borhan MH, Holub EB, Beynon JL, Rozwadowski K, Rimmer SR: The arabidopsis TIR-NB-LRR gene RAC1 confers resistance to Albugo candida (white rust) and is dependent on EDS1 but not PAD4. Mol Plant Microbe Interact 2004, 17(7):711-719. 5. Chang X, Han J: Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors. Mol Carcinog 2006, 45(3):183-196. 6. Chang X, Han J, Pang L, Zhao Y, Yang Y, Shen Z: Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer 2009, 9:40. 7. Das K, Butler GH, Kwiatkowski V, Clark AD, Jr., Yadav P, Arnold E: Crystal structures of arginine deiminase with covalent reaction intermediates; implications for catalytic mechanism. Structure 2004, 12(4):657-667. 8. Feun L, Savaraj N: Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs 2006, 15(7):815-822. 9. Foulquier C, Sebbag M, Clavel C, Chapuy-Regaud S, Al Badine R, Mechin MC, Vincent C, Nachat R, Yamada M, Takahara H et al: Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 2007, 56(11):3541-3553. 10. Galkin A, Lu X, Dunaway-Mariano D, Herzberg O: Crystal structures representing the Michaelis complex and the thiouronium reaction intermediate of Pseudomonas aeruginosa arginine deiminase. J Biol Chem 2005, 280(40):34080-34087. 11. Gyorgy B, Toth E, Tarcsa E, Falus A, Buzas EI: Citrullination: a posttranslational modification in health and disease. Int J Biochem Cell Biol 2006, 38(10):1662-1677. 12. Jones JE, Causey CP, Knuckley B, Slack-Noyes JL, Thompson PR: Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential. Curr Opin Drug Discov Devel 2009, 12(5):616-627. 13. Kearney PL, Bhatia M, Jones NG, Yuan L, Glascock MC, Catchings KL, Yamada M, Thompson PR: Kinetic characterization of protein arginine deiminase 4: a transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis. Biochemistry 2005, 44(31):10570-10582. 14. Klose RJ, Zhang Y: Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol 2007, 8(4):307-318. 15. Knuckley B, Causey CP, Jones JE, Bhatia M, Dreyton CJ, Osborne TC, Takahara H, Thompson PR: Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3. Biochemistry 2010, 49(23):4852-4863. 16. Knuckley B, Luo Y, Thompson PR: Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg Med Chem 2008, 16(2):739-745. 17. Li P, Yao H, Zhang Z, Li M, Luo Y, Thompson PR, Gilmour DS, Wang Y: Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol 2008, 28(15):4745-4758. 18. Liao YF, Hsieh HC, Liu GY, Hung HC: A continuous spectrophotometric assay method for peptidylarginine deiminase type 4 activity. Anal Biochem 2005, 347(2):176-181. 19. Ni Y, Schwaneberg U, Sun ZH: Arginine deiminase, a potential anti-tumor drug. Cancer Lett 2008, 261(1):1-11. 20. Shirai H, Blundell TL, Mizuguchi K: A novel superfamily of enzymes that catalyze the modification of guanidino groups. Trends Biochem Sci 2001, 26(8):465-468. 21. Shirai H, Mokrab Y, Mizuguchi K: The guanidino-group modifying enzymes: structural basis for their diversity and commonality. Proteins 2006, 64(4):1010-1023. 22. Slack JL, Causey CP, Thompson PR: Protein arginine deiminase 4: a target for an epigenetic cancer therapy. Cell Mol Life Sci 2011, 68(4):709-720. 23. Slack JL, Jones LE, Jr., Bhatia MM, Thompson PR: Autodeimination of protein arginine deiminase 4 alters protein--protein interactions but not activity. Biochemistry 2011, 50(19):3997-4010. 24. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ: PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003, 25(11):1106-1118. 25. Wang L, Chang X, Yuan G, Zhao Y, Wang P: Expression of peptidylarginine deiminase type 4 in ovarian tumors. Int J Biol Sci 2010, 6(5):454-464. 26. Zhang J, Dai J, Zhao E, Lin Y, Zeng L, Chen J, Zheng H, Wang Y, Li X, Ying K et al: cDNA cloning, gene organization and expression analysis of human peptidylarginine deiminase type VI. Acta Biochim Pol 2004, 51(4):1051-1058.
摘要: 人類胜肽精胺酸去亞胺酶 (peptidylarginine deiminase,PAD) 為需要鈣離子存在下才有活性的酵素,在轉譯後修飾中將目標蛋白上的arginine轉變成citrulline,此反應稱為protein citrullination (deimination)。PAD4是唯一擁有nuclear localization signal (NLS) 的異構型,NLS可以幫助細胞將PAD4運送進細胞核。近年來許多研究指出PAD4與許多疾病有關,例如:類風濕性關節炎 (RA)、惡性腫瘤等。PAD4與受質結合狀態下的結構已被解出,但對於PAD4如何辨識受質仍然不清楚,為了探討PAD4對受質專一性的關係,利用定點突變修改PAD4與受質結合位置上的胺基酸,將目標胺基酸修改成alanine 和相似類型的胺基酸,以酵素動力學實驗分析突變後酵素對peptidylarginine的活性。再透過生物資訊的方法比對guanidino-group modifying enzymes 上的胺基酸,找出PAD4與arginine deiminase差異的胺基酸,並修改為相同胺基酸,然後進行酵素動力學實驗分析對 arginine活性。由實驗結果得知R372、V469、W347在PAD4上為不可取代的胺基酸,R374、R639對活性影響較小;而S406突變為aspartate和glutamate不能增加PAD4對arginine的活性。
Peptidylarginine deiminase (PAD) is a Ca+2-dependent enzyme that can catalyse the conversion of arginine residue to citrulline in protein in posttranslational modification and the reaction is named citrullination or deimination . PAD4 is only one isotype with nuclear localization signal (NLS) that can help cell transfer PAD4 into nucleus . Recently, some researches indicates a relationship between PAD4 and many disease including RA and cancer . The structure of PAD4 with substrate was resolved but it is still unknown how to recognize the substrate of PAD4. To study the substrate specificity of PAD4, we mutated the amino acid of substrate binding site to Ala or similar amino acids, then analysed the activity by kinetic assay . Determining the difference between PAD4 and guanidine-group modifying enzymes though bioinformation, we replaced residues of PAD4 with same residue of the other guanidine-group modifying enzymes by site-directed mutagenesis and analysed different substrate by enzyme kinetic assay. Results suggested R372, V469 and W347 cannot be substituted for other amino acids, R374 and R639 are less influential on activity;replacing S406 with Asp and Glu cannot increase the activity of PAD4 for Arg.
URI: http://hdl.handle.net/11455/23735
其他識別: U0005-1808201118525700
Appears in Collections:生命科學系所

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.